Biological toxicities as surrogate markers of efficacy in patients treated with mTOR inhibitors for metastatic renal cell carcinoma

M. Jebali,Reza-Thierry Elaidi,Mara Brizard,J. Fouque,C Takouchop,Brigitte Sabatier,S. Oudard,J. Medioni

Biological toxicities as surrogate markers of efficacy in patients treated with mTOR inhibitors for metastatic renal cell carcinoma

2017

M. Jebali
Reza-Thierry Elaidi
Mara Brizard
J. Fouque
C Takouchop
Brigitte Sabatier
S. Oudard
J. Medioni

Background Metabolic toxicities of mTOR inhibitors (mTORi) are well characterized. The purpose of the study was to investigate the relationship between these metabolic toxicities and mTORi efficacy.

Keywords:

Pathology
Discovery and development of mTOR inhibitors
Cancer research
Medicine
Surgical oncology
Renal cell carcinoma
Biomarker (medicine)
Hypophosphatemia
Progression-free survival
Temsirolimus
Progressive disease
Creatinine
Diabetes mellitus
Everolimus

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations